Novartis Venture Fund, a founding investor, co-led a $65m series A round to launch cancer treatment developer Twentyeight-Seven Therapeutics.

US-based cancer-focused biotechnology developer Twentyeight-Seven Therapeutics (28-7) launched on Thursday with $65m in series A funding co-led by Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis. Investment firm MPM Capital co-led the round, which also featured Johnson & Johnson Innovation – JJDC and Astellas Venture Management, the respective corporate venture capital units…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.